Loading...

World-Class Retina Care. Community-Based Caring.

Can Ozempic Affect Your Eyes or Vision?

Posted On May 21, 2025 / By / Posted in Blog

Can Ozempic Affect Your Eyes or Vision?

Initially approved by the U.S. Food and Drug Administration (FDA) to help control blood sugar and treat type 2 diabetes, semaglutide (brand names Ozempic, Wegovy and Rybelsus) has also emerged as a

read more
Posted On May 14, 2025 / By / Posted in Blog

Texas Retina Associates Participating in Phase III Clinical Trial for Choroidal Melanoma

Under the leadership of principal investigator Timothy Fuller, MD, Texas Retina is participating in the Phase III AU-011 clinical trial (CoMpass) for treatment of small choroidal (ocular) melanoma. Together with Aura Biosciences,

read more
Posted On May 13, 2025 / By / Posted in Blog

Dr. Wang Presented Study Results of New Wet AMD Treatment Approach at the ARVO 2025 Meeting

On May 9, 2025, Texas Retina’s Robert C. Wang, MD, presented “Top Line Results from ODYSSEY: A Phase IIb Study of Suprachoroidally Administered CLS-AX in Participants with Neovascular Age-related Macular Degeneration” at

read more
Posted On April 29, 2025 / By / Posted in Blog

Dr. Abbey Shares 36-Month Results of Pegcetacoplan Treatment for Geographic Atrophy in AMD

On behalf of the investigators for the OAKS, DERBY, and GALE clinical trials, Texas Retina’s Director of Clinical Research for Dallas, Ashkan Abbey, MD, co-authored an article titled, “Pegcetacoplan Treatment for Geographic

read more
Posted On April 7, 2025 / By / Posted in Blog

Dr. Laura Discussed Dry AMD Treatment at 2025 Vit-Buckle Society Annual Meeting

Texas Retina’s Diana M. Laura, MD, participated in a debate at the 13th Annual Vit-Buckle Society Meetingheld recently in Austin, Texas, where she discussed the role of complement inhibitors for the treatment

read more
Posted On January 7, 2025 / By / Posted in Blog

Dr. Anand Participated in Research on New Gene Therapy Drug for X-linked Retinitis Pigmentosa Published in American Journal of Ophthalmology

The two-year results of the Phase I/II, multi-center HORIZON clinical trial of the new subretinal gene therapy drug AGTC-501 for X-linked retinitis pigmentosa were recently published in the American Journal of Ophthalmology.

read more
Posted On December 30, 2024 / By / Posted in Blog

Happy New Year!

Happy New Year! Our offices will be closed on Wednesday, January 1, 2025. As another year comes to a close, we want to thank all of our patients, referring physicians, neighbors and

read more
Posted On December 9, 2024 / By / Posted in Blog

Keep an Eye on Safety When Choosing Holiday Gifts

Air, BB, pellet and paintball guns may be on children’s holiday wish lists, but are they safe? Eye Injuries from Projectile Toys on the Rise Eye injuries from these types of guns

read more
Posted On November 21, 2024 / By / Posted in Blog

How Smoking Can Affect Your Eye Health

Today is the Great American Smokeout. Smoking remains the single largest cause of preventable disease and premature death in the United States. You probably know that smoking increases your risk of developing

read more
Posted On October 9, 2024 / By / Posted in Blog

Dr. Abbey Participated in Roundtable Discussion on Newer Therapies for Wet AMD and Diabetic Macular Edema

Texas Retina’s Ashkan Abbey, MD, recently participated in a roundtable discussion on “Navigating Wet AMD and DME Using Newer Therapies” available on Eyetube. Dr. Abbey and fellow panelist Scott Walter, MD, MSc,

read more